NCT00849355 - Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2010

Conditions

No Hodgkin B Lymphoma

Interventions

DRUG

RCOMP-14 + rituximab

"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."

Trial Locations (12)

12004

ACTIVE_NOT_RECRUITING

Hospital de Castellon, Castellon

28211

NOT_YET_RECRUITING

Hospital Severo Ochoa, Madrid

28220

ACTIVE_NOT_RECRUITING

Hospital Universitario Puerta de Hierro, Madrid

30008

NOT_YET_RECRUITING

Hospital Morales Messeguer, Murcia

30203

NOT_YET_RECRUITING

Hospital Santa Mª del Rosell, Murcia

46014

ACTIVE_NOT_RECRUITING

Hospital general universitario de Valencia, Valencia

46015

ACTIVE_NOT_RECRUITING

H. Arnau de Vilanova, Valencia

46017

ACTIVE_NOT_RECRUITING

Hospital Universitario Dr. Peset, Valencia

08003

ACTIVE_NOT_RECRUITING

hospital del Mar, Barcelona

08035

ACTIVE_NOT_RECRUITING

Hospital Vall D'Hebrón, Barcelona

Unknown

RECRUITING

Hospital de Getafe, Madrid

07198

ACTIVE_NOT_RECRUITING

Hospital son Llatzer, Mallorca